Wockhardt is a global pharmaceutical and biotechnology organisation, providing affordable, high-quality medicines. It is India’s leading research-based global healthcare enterprise with relevance in the fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Speciality Hospitals.
Wockhardt is a true Indian Multi-National Company with a multi-ethnic workforce of 8600 Wockhardt Associates from 21 different nationalities globally. It has 3 research centres and 12 manufacturing plants, with businesses ranging from the manufacture and marketing of Pharmaceutical and Bio-pharmaceutical formulations, Active Pharmaceutical Ingredients (APIs) and Vaccines.
Murtaza Khorakiwala, managing director of Wockhardt, discusses the company’s vast international expertise in the manufacturing of pharmaceuticals and biopharmaceutical formulations in their 12 US FDA, UK MHRA and EMA compliant…
Sir Dr. Huz, CEO and trustee of the Wockhardt Foundation and executive director of Wockhardt, discusses the role the Foundation plays in low- and middle-income areas across India, and how integrating simple…
Juan Francisco Hernández, general manager of Latin America at Wockhardt, showcases the added value of the company to the entire region based on quality, safety and cost-effective medicines targeting diabetes,…
You joined Wockhardt in 2000; you became a member of the board in 2006, and were appointed managing director in 2009. The Indian industry has undergone many changes in the…
As a young pathbreaking transformer in the Indian pharmaceutical landscape, Yogesh Agrawal, managing director of Ajanta Pharma Ltd., shares his desire to accelerate the company’s expansion in the US. Out…
Sanjay Bhutani, managing director of Bausch & Lomb India and SAARC operations, gives his insights into the thriving visual care industry which has allowed the company to launch 31 intraocular…
At the Organization of Pharmaceuticals Producers of India (OPPI), the association representing the research-based pharmaceutical companies in India, putting the patient at the center of all that they do is…
Bhupendra Singh, chairman of the Indian National Pharmaceutical Pricing Authority (NPPA), provides an overview of the current mechanisms governing the pharmaceutical and life sciences industry in India, highlighting the challenges…
Sir Dr. Huz, CEO and trustee of the Wockhardt Foundation and executive director of Wockhardt, discusses the role the Foundation plays in low- and middle-income areas across India, and how integrating simple…
The secretary-general of the Indian Drug Manufacturers Association (IDMA) gives his insight into the current state of the Indian pharma industry, the IDMA’s role in raising the quality of Indian-made…
The Indian joint secretary for commerce and industry, interviewed at CPhI Worldwide 2014 in Paris, discusses India’s place in the global pharmaceutical landscape, and emphasizes the country’s contribution to the…
You have only recently been appointed Managing Director for the first time in your career. How did your first year with UCB India go so far? My first year at…
The Indian biotechnology sector is quite particular. In spite of its young age, the industry has grown significantly in a very short time. In your view, where does the Indian…
Novo Nordisk seems somewhat of an exception to the MNCs that recently entered India, as it already set up its HQ in Bangalore in 1994. How do you explain this…
PAREXEL has had a long-term commitment to India. Could you give us a brief overview of your activities in the country? PAREXEL offers clinical development services throughout India. In 2004,…
TCS Life Sciences and Healthcare vertical was created within the Tata Group 10 years ago. Can you explain to the readers, how such a diversified group such as Tata decided…
See our Cookie Privacy Policy Here
